122 results
8-K
CHRS
Coherus Biosciences Inc
9 May 24
Entry into a Material Definitive Agreement
7:30am
, such as expense reimbursement, as well as indemnification rights for the benefit of the Agent and the Lenders.
The foregoing description of the material terms
8-K
EX-99.1
n26 6zsgdlvjlmfc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
8-K
EX-99.1
m825b s1alt8cdi
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
8-K
EX-99.2
b0xi67
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
8-K
EX-99.1
l0j86t7q97q qx57b
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K
EX-2.1
jli84k
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K/A
EX-99.1
1wxtqte ensv
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K
EX-99.1
3atso
27 Oct 23
Regulation FD Disclosure
4:19pm
424B5
jf91clkc
12 Sep 23
Prospectus supplement for primary offering
6:04am